Published in Ther Clin Risk Manag on December 01, 2008
Tracheobronchial manifestations of Aspergillus infections. ScientificWorldJournal (2011) 1.37
Fungal infections: their diagnosis and treatment in transplant recipients. Int J Hepatol (2012) 0.79
Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran. World J Crit Care Med (2014) 0.75
Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury. Dose Response (2017) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 9.84
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med (2002) 9.21
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med (2002) 7.85
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis (2002) 7.81
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother (2005) 5.35
Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis (2006) 5.27
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis (2006) 5.27
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis (2007) 4.23
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother (2000) 4.03
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis (2005) 3.96
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med (2001) 3.95
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med (2002) 3.33
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis (2004) 3.22
A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med (2006) 3.12
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis (2004) 3.10
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med (2005) 2.70
Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis (2001) 2.51
Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med (2007) 2.41
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2003) 2.40
Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol (2005) 2.38
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med (1999) 2.35
Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol (2005) 2.22
Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother (2004) 2.13
Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg (2008) 2.10
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis (2007) 2.09
Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol (2004) 2.04
Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol (2005) 2.00
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis (2006) 1.89
False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med (2003) 1.86
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother (2007) 1.82
Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med (2004) 1.81
Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care (2002) 1.78
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis (2008) 1.75
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med (1997) 1.70
Post mortem examination in the intensive care unit: still useful? Intensive Care Med (2004) 1.66
Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.63
Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg (2001) 1.63
Micafungin: a new echinocandin. Clin Infect Dis (2006) 1.58
Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev (2006) 1.55
Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis (2006) 1.52
Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer (2002) 1.50
Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl (2006) 1.49
Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly (2002) 1.41
Fungal infections in solid organ transplantation. Med Mycol (2007) 1.39
Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol (2005) 1.38
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother (2006) 1.34
Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother (2003) 1.33
Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med (2005) 1.30
Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant (2003) 1.27
Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis (2003) 1.21
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer (2007) 1.19
Fungal infections in solid organ transplantation. Expert Opin Pharmacother (2006) 1.15
Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect (2005) 1.11
Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med (2002) 1.10
Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med (1997) 1.05
Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ (2001) 1.04
Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis (2006) 1.04
Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl (2006) 1.04
Fungal infections after lung transplantation. Transplant Rev (Orlando) (2008) 1.04
Voriconazole prophylaxis in lung transplant recipients. Am J Transplant (2006) 1.04
Preemptive treatment of fungal infection based on plasma (1 --> 3)beta-D-glucan levels after liver transplantation. Infection (2007) 1.02
Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv (2006) 1.02
Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet (2004) 1.02
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother (2006) 1.01
A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis (2004) 0.98
Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis (2006) 0.97
The radiological spectrum of pulmonary aspergillosis. Med Mycol (2005) 0.97
Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care (2007) 0.97
Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol (2004) 0.97
Is there a role for antibody testing in the diagnosis of invasive candidiasis? Rev Iberoam Micol (2004) 0.96
Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation (1988) 0.94
Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis (1996) 0.94
Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation (2003) 0.93
Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol (2006) 0.92
Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother (2003) 0.92
Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis (1997) 0.92
Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis (2000) 0.91
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation (2001) 0.91
[Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis]. Enferm Infecc Microbiol Clin (2004) 0.90
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med (2014) 2.95
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica (2008) 2.32
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]. Med Clin (Barc) (2012) 2.02
[Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch Bronconeumol (2008) 1.75
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis (2014) 1.73
Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther (2009) 1.68
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma (2006) 1.65
[HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)]. Enferm Infecc Microbiol Clin (2009) 1.57
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol (2010) 1.57
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood (2013) 1.54
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis (2003) 1.54
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50
Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother (2004) 1.50
Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk Lymphoma (2013) 1.43
Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review. Int J Rheum Dis (2014) 1.40
[Lung transplantation for cystic fibrosis: infectious events]. Med Clin (Barc) (2006) 1.39
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica (2013) 1.32
Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother (2012) 1.31
Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant (2006) 1.28
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. Diagn Microbiol Infect Dis (2003) 1.25
Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother (2013) 1.19
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res (2008) 1.17
Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother (2011) 1.17
Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. Int J Food Microbiol (2006) 1.14
Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant (2009) 1.14
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol (2009) 1.14
Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study. Antimicrob Agents Chemother (2005) 1.13
Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol (2012) 1.12
Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother (2003) 1.11
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS (2012) 1.09
Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis (2004) 1.08
In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother (2010) 1.08
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother (2006) 1.08
Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter (2013) 1.06
Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev Anti Infect Ther (2009) 1.04
Fungal infections after lung transplantation. Transplant Rev (Orlando) (2008) 1.04
Disseminated histoplasmosis with hemophagocytic syndrome in a patient with AIDS: description of one case and review of the Spanish literature. Rev Iberoam Micol (2007) 1.01
Antifungal activity against Candida biofilms. Int J Artif Organs (2012) 1.01
Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother (2005) 0.98
Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species. J Clin Microbiol (2011) 0.97
Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J Antimicrob Chemother (2012) 0.96
Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant (2009) 0.93
A positional scanning combinatorial library of peptoids as a source of biological active molecules: identification of antimicrobials. J Comb Chem (2003) 0.92
[Epidemiology of candidemia in Spain - Multicenter study] Rev Iberoam Micol (2002) 0.92
Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol (2013) 0.91
Differentiation of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis by specific PCR amplification of the RPS0 intron. Int J Med Microbiol (2011) 0.90
Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica (2008) 0.90
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob Agents Chemother (2009) 0.90
Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. J Antimicrob Chemother (2007) 0.89
Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection. Rev Esp Quimioter (2010) 0.89
Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period. Diagn Microbiol Infect Dis (2007) 0.88
Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag (2006) 0.86
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother (2002) 0.85
Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol (2006) 0.85
Fungal infections after lung transplantation. Curr Opin Pulm Med (2009) 0.85
Timing of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 0.84
Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates. Diagn Microbiol Infect Dis (2011) 0.84
[Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study]. Rev Iberoam Micol (2011) 0.84
Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant (2013) 0.83
Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission. Haematologica (2002) 0.83
Comparison of posaconazole and voriconazole in vitro killing against Candida krusei. Diagn Microbiol Infect Dis (2008) 0.83
Limbic encephalitis and related cortical syndromes. Curr Treat Options Neurol (2013) 0.83
[Value of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients]. Rev Iberoam Micol (2003) 0.82
Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination. Mediterr J Hematol Infect Dis (2012) 0.82
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res (2002) 0.82
[Purulent pericarditis due to Salmonella enterica subsp. arizonae]. Enferm Infecc Microbiol Clin (2002) 0.82
Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods. J Antimicrob Chemother (2012) 0.82
Guidelines for the selection of lung transplantation candidates. Arch Bronconeumol (2011) 0.82
Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns. J Clin Microbiol (2006) 0.82
A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics (2006) 0.82
Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. J Clin Microbiol (2011) 0.81